Amarin Corp Plc (AMRN)

[Babr]

People die of hypoxemia caused by an inflammatory response in the lungs to fight the virus, this results is ARDS type of picture, it is certainly possible that Vascepa can help these victims in that regard. It is certainly not an acute quick response to EPA, meaning that if u have COVID now take two weeks of EPA and you will be OK .it is probably the same mode of action that we don’t quite understand taking place over the years. In addition it most likely offers benefits in terms of the cardiovascular complications, again this is probably in patients who have been on the meds for a while prior to when they get infected. On the other hand ,we need inflammation to fight pathogens and less inflammation may not be a good thing so there has to be a balance that needs to be achieved, but if I have to guess from one I know so far, I have to say Vascepa patients may end up on the positive end.It is complicated, look at the controversy of NSAIDS in COVID patients.